Published online Nov 14, 2019. doi: 10.3748/wjg.v25.i42.6311
Peer-review started: August 19, 2019
First decision: September 10, 2019
Revised: October 16, 2019
Accepted: November 1, 2019
Article in press: November 1, 2019
Published online: November 14, 2019
Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant gastrointestinal cancers worldwide. Current diagnostic methods and therapeutic strategies are very limited, and the prognosis of pancreatic cancer patients remains poor. To understand the molecular mechanisms of pancreatic cancer development is necessary and urgent. Little is known regarding miR-30c expression and its role in the progression of PDAC.
Our study will provide a new therapeutic target for pancreatic cancer.
To study the expression, role, and target gene of miR-30c in pancreatic cancer.
We detected the expression levels of miR-30c and twinfilin 1 (TWF1) in Gene Expression Omnibus datasets and validated in clinical samples by quantitative real-time polymerase chain reaction. The relationship of miR-30c expression with clinicopathological factors of pancreatic cancer patients was analyzed. The effect and mechanism miR-30c on pancreatic cancer cell proliferation were investigated in vitro and in vivo. Assays were performed to explore potential target gene TWF1 of miR-30c in pancreatic cancer.
In the present study, we found that miR-30c was downregulated and associated with a poor prognosis in pancreatic cancer patients. We showed that re-expression of miR-30c reduced pancreatic cancer cell proliferation in vitro and in vivo by targeting TWF1. Meanwhile, overexpression of TWF1 abolished the effects of miR-30c in pancreatic cancer.
MiR-30c is downregulated and promotes the proliferation of pancreatic cancer cells by targeting TWF1. Overexpression of TWF1 abolishes the effects of miR-30c.
This study provides insight into the role of miR-30c in promoting pancreatic cancer development by targeting TWF1. MiR-30c might be a new therapeutic target for pancreatic cancer.